Lanabecestat phase 3 trials were stopped for futility, adding class-level pressure against broad BACE1 inhibition as an Alzheimer's disease treatment strategy.

Evidence span

Lanabecestat phase 3 trials were stopped for futility, adding class-level pressure against broad BACE1 inhibition as an Alzheimer's disease treatment strategy.

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Early and mild Alzheimer's disease BACE inhibitor trials; futility stopping.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required